ProCE Banner Activity

Phase III QUAZAR AML-001: Analyses of CC-486 (Oral Azacitidine) vs Placebo as Maintenance Therapy in AML After CR/CRi

Slideset Download
Conference Coverage
New data for CC-486 maintenance therapy in AML support a new escalated 21-day dosing schedule for patients who experience relapse with ≤ 15% blasts and an overall preservation of health-related quality of life.

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology